These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 15647208)

  • 1. Differential modulation of p38 mitogen activated protein kinase and STAT3 signalling pathways by infliximab and etanercept in intestinal T cells from patients with Crohn's disease.
    Rosenstiel P; Agnholt J; Kelsen J; Medici V; Waetzig GH; Seegert D; Schreiber S
    Gut; 2005 Feb; 54(2):314-5; author reply 316-6. PubMed ID: 15647208
    [No Abstract]   [Full Text] [Related]  

  • 2. Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease.
    Di Sabatino A; Ciccocioppo R; Cinque B; Millimaggi D; Morera R; Ricevuti L; Cifone MG; Corazza GR
    Gut; 2004 Jan; 53(1):70-7. PubMed ID: 14684579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infliximab induced T lymphocyte apoptosis in Crohn's disease.
    van den Brande J; Hommes DW; Peppelenbosch MP
    J Rheumatol Suppl; 2005 Mar; 74():26-30. PubMed ID: 15742461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease.
    Van den Brande JM; Braat H; van den Brink GR; Versteeg HH; Bauer CA; Hoedemaeker I; van Montfrans C; Hommes DW; Peppelenbosch MP; van Deventer SJ
    Gastroenterology; 2003 Jun; 124(7):1774-85. PubMed ID: 12806611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diverse effects of infliximab and etanercept on T lymphocytes.
    Sieper J; Van Den Brande J
    Semin Arthritis Rheum; 2005 Apr; 34(5 Suppl1):23-7. PubMed ID: 15852251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of Crohn's disease following anti-tumour necrosis factor therapy (etanercept).
    Yazisiz V; Avci AB; Erbasan F; Yildirim B; Terzioğlu E
    Colorectal Dis; 2008 Nov; 10(9):953-4. PubMed ID: 18294265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infliximab reduces the number of activated mucosal lymphocytes in patients with Crohn's disease.
    Ferkolj I; Ihan A; Markovic S; Veceric Z; Pohar M
    J Gastrointestin Liver Dis; 2006 Sep; 15(3):231-5. PubMed ID: 17013447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Etanercept for Crohn's disease.
    Travers SB
    N Engl J Med; 2004 Feb; 350(8):840; author reply 840. PubMed ID: 14973205
    [No Abstract]   [Full Text] [Related]  

  • 9. Functional modulation of Crohn's disease myofibroblasts by anti-tumor necrosis factor antibodies.
    Di Sabatino A; Pender SL; Jackson CL; Prothero JD; Gordon JN; Picariello L; Rovedatti L; Docena G; Monteleone G; Rampton DS; Tonelli F; Corazza GR; MacDonald TT
    Gastroenterology; 2007 Jul; 133(1):137-49. PubMed ID: 17631138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor necrosis factor and its blockade in granulomatous infections: differential modes of action of infliximab and etanercept?
    Ehlers S
    Clin Infect Dis; 2005 Aug; 41 Suppl 3():S199-203. PubMed ID: 15983900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of monocyte chemoattractant protein 1 (MCP-1) release by explants of human visceral adipose tissue.
    Fain JN; Madan AK
    Int J Obes (Lond); 2005 Nov; 29(11):1299-307. PubMed ID: 15997242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Profile of soluble cytokine receptors in Crohn's disease.
    Gustot T; Lemmers A; Louis E; Nicaise C; Quertinmont E; Belaiche J; Roland S; Van Gossum A; Devière J; Franchimont D
    Gut; 2005 Apr; 54(4):488-95. PubMed ID: 15753533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Do anti-tumor necrosis factors induce response and remission in patients with acute refractory Crohn's disease? A systematic meta-analysis of controlled clinical trials.
    Rahimi R; Nikfar S; Abdollahi M
    Biomed Pharmacother; 2007 Jan; 61(1):75-80. PubMed ID: 17184965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD19+ in intestinal mucosa predict the response to infliximab in Crohn's disease.
    Ferkolj I; Ihan A; Markovic S
    Hepatogastroenterology; 2005; 52(64):1128-33. PubMed ID: 16001645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of the novel Th17 cytokine IL-26 in intestinal inflammation.
    Dambacher J; Beigel F; Zitzmann K; De Toni EN; Göke B; Diepolder HM; Auernhammer CJ; Brand S
    Gut; 2009 Sep; 58(9):1207-17. PubMed ID: 18483078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reactivation of latent granulomatous infections by infliximab.
    Wallis RS; Broder M; Wong J; Lee A; Hoq L
    Clin Infect Dis; 2005 Aug; 41 Suppl 3():S194-8. PubMed ID: 15983899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early changes in rectal nitric oxide and mucosal inflammatory mediators in Crohn's colitis in response to infliximab treatment.
    Ljung T; Axelsson LG; Herulf M; Lundberg JO; Hellström PM
    Aliment Pharmacol Ther; 2007 Apr; 25(8):925-32. PubMed ID: 17402996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytokines and mucosal inflammatory response in Crohn's disease.
    van Deventer SJ
    Eur J Surg; 1998 Dec; 164(12):897-901. PubMed ID: 10029384
    [No Abstract]   [Full Text] [Related]  

  • 19. Prediction of response to infliximab in Crohn's disease.
    Chaudhary R; Ghosh S
    Dig Liver Dis; 2005 Aug; 37(8):559-63. PubMed ID: 15893967
    [No Abstract]   [Full Text] [Related]  

  • 20. Immunology of cutaneous vasculitis associated with both etanercept and infliximab.
    Srivastava MD; Alexander F; Tuthill RJ
    Scand J Immunol; 2005 Apr; 61(4):329-36. PubMed ID: 15853915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.